Medtronic currently markets the MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System - the world's first insulin pump with REAL-Time continuous glucose monitoring. The MiniMed Paradigm REAL-Time System has all of the benefits of CGM plus the added value of precise insulin delivery through the use of insulin pump therapy. The Guardian REAL-Time System, a stand-alone CGM device, will be available later this year.

Children with Diabetes Statistics


* More than one million patients in the US have type 1 diabetes, often referred to as juvenile diabetes.1
* Of the 30,000 new patients diagnosed with type 1 diabetes every year, almost half, or 13,000 patients, are children.2
* There are more than 175,000 type 1 diabetes patients under 20 years of age.3 More than one in every 600 children globally has type 1 diabetes,4 and recent studies suggest that the global incidence in children and adolescents is increasing by roughly 3 percent annually.5
* According to the American Diabetes Association, almost 21 million Americans (seven percent of the population) have diabetes.6
* Diabetes is the fifth-deadliest disease in the United States,7 affecting children and adults, and costing the United States more than $132 billion in direct and indirect costs.8
* About 28 percent of diabetes patients use insulin to control their disease.9 That means almost six million Americans require insulin to manage their diabetes.

About the Diabetes Business at Medtronic
The diabetes business at Medtronic (www.medtronic-diabetes.com) is the world leader in diabetes management. The company's products include insulin pump therapy, continuous glucose monitoring systems, related disposable products and diabetes management software.

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology, alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results.

Citations:
1 US Opportunities in Drug Delivery Technologies published by Health Research International in July 2004

2 http://www.cdc.gov/diabetes/projects/cda2.htm

4 http://diabetes.org/diabetes-statistics/prevalence.jsp

More Voices